spacer
home > epc > spring 2018 > early beginnings
PUBLICATIONS
European Pharmaceutical Contractor

Early Beginnings

Moving a promising drug candidate from the laboratory to first-in-human (FIH) trials is a complex, multistage challenge. Coordinating the formulation development steps, manufacturing, and logistics involved requires careful management and planning.

Integrating the process in collaboration with expert vendors offers drug developers an efficient, cost-effective pathway to success in early phase development. Furthermore, experienced contractors can help drug companies avoid the early phase pitfalls that can see projects fail at a later stage.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
1
     

There are no comments in regards to this article.

spacer
Dr Torkel Gren is General Manager at Recipharm Pharmaceutical Development. Torkel holds degrees in pharmacy and business administration, as well a PhD in Pharmaceutics from Uppsala University, Sweden. He has worked in the pharma industry since 1988 and has held a number of scientist and manager positions in Europe and the US. Torkel was lead formulator and co-inventor of Detrol OD/Detrusitol SR. He is a member of the board of the Swedish Pharmaceutical Society.

Anders Millerhovf is CEO at CTC Clinical Trial Consultants. He holds a degree in medical biology from Linköping University, Sweden. Anders has worked in the life sciences industry since 2002 and has been focused on Phase 0-2a projects in various management and director positions. He has been a partner at CTC since 2012.
spacer
Dr Torkel Gren
spacer
spacer
spacer
Anders Millerhovf
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement